Vergelijking

Enfuvirtid vs. Ganirelix

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

159519-65-0

123246-29-7

Molecuulmassa

4491.88 g/mol

1570.3 g/mol

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Enfuvirtid

Enfuvirtide binds the first heptad-repeat region (HR1) of the gp41 subunit of the HIV envelope protein. This prevents the conformational change required for fusion of the viral and cell membranes — the virus cannot enter the cell.

Ganirelix

Ganirelix competitively and reversibly binds the pituitary GnRH receptor, rapidly suppressing LH (and, less so, FSH) release — without the initial hormone 'flare' of GnRH agonists.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Enfuvirtid	Ganirelix
Duitsland	Op recept	Op recept
Verenigde Staten	Op recept	Op recept

Volledige vermeldingen

Enfuvirtid

Volledige vermelding →

Ganirelix

Volledige vermelding →

Frequently asked questions

What is the difference between Enfuvirtid and Ganirelix?: Enfuvirtid is classified as "Onderzoek (overig)", while Ganirelix is classified as "Onderzoek (overig)". Enfuvirtid: Enfuvirtide is a synthetic 36-amino-acid peptide and the first HIV-1 fusion inhibitor. It binds the HR1 region of the viral envelope protein gp41, blocking viral entry into the cell. Approved for treatment-experienced HIV patients. Ganirelix: Ganirelix is a synthetic decapeptide and GnRH antagonist. In assisted reproduction (IVF) it prevents the premature LH surge during controlled ovarian stimulation. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Enfuvirtid or Ganirelix?: The highest available evidence level is "Humane RCT" for Enfuvirtid and "Humane RCT" for Ganirelix. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Enfuvirtid and Ganirelix in Germany and the United States?: Duitsland: Enfuvirtid — Op recept, Ganirelix — Op recept. Verenigde Staten: Enfuvirtid — Op recept, Ganirelix — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Enfuvirtid

Ganirelix

Duitsland

Op recept

Verenigde Staten

Op recept

Frequently asked questions

What is the difference between Enfuvirtid and Ganirelix?

Enfuvirtid is classified as "Onderzoek (overig)", while Ganirelix is classified as "Onderzoek (overig)". Enfuvirtid: Enfuvirtide is a synthetic 36-amino-acid peptide and the first HIV-1 fusion inhibitor. It binds the HR1 region of the viral envelope protein gp41, blocking viral entry into the cell. Approved for treatment-experienced HIV patients. Ganirelix: Ganirelix is a synthetic decapeptide and GnRH antagonist. In assisted reproduction (IVF) it prevents the premature LH surge during controlled ovarian stimulation. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Enfuvirtid or Ganirelix?

The highest available evidence level is "Humane RCT" for Enfuvirtid and "Humane RCT" for Ganirelix. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Enfuvirtid and Ganirelix in Germany and the United States?

Duitsland: Enfuvirtid — Op recept, Ganirelix — Op recept. Verenigde Staten: Enfuvirtid — Op recept, Ganirelix — Op recept. These are factual summaries with source and review date on the individual pages.